Treatment with SGLT2 inhibitors in elderly patients with HFrEF and CKD was associated with a lower rate of all-cause mortality (HR 0.324; 95% CI 0.117-0.894).
Observational (n=173)
No
Do SGLT2 inhibitors reduce mortality in very elderly patients with HFrEF and CKD?
In a real-world cohort of very elderly patients with HFrEF and CKD, SGLT2 inhibitor use was associated with significantly reduced all-cause mortality.
Effect estimate: HR 0.324 (95% CI 0.117-0.894)
Background: Heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) are common in the growing population of elderly patients, yet little evidence specifically targeting this population exists. The purpose of this study is to analyze the effect of SGLT2 inhibition in this cohort. Methods: A single-center, real-world observational study was performed. Patients aged >75 with HFrEF and CKD and theoretical indication for sodium–glucose cotransporter 2 (SGLT2) inhibitors were enrolled. Results: A total of 173 patients were included, with a mean age of 84.7 years, mean left ventricle ejection fraction of 29.5% and estimated glomerular filtration rate of 45.9 mL/min/1.73 m2. During a median follow-up of 39 months, 73 (42.2%) deaths from any cause and 95 (53.3%) major clinical events (composite of mortality and heart failure admission) were recorded. Multivariate Cox proportional hazards regression analyses were performed to identify associated variables, and SGLT2 inhibition showed to be a protective factor for the mortality endpoint (hazard ratio 0.324 0.117–0.894). Male sex was shown to be a risk factor for both endpoints, diabetes mellitus for the mortality endpoint and diuretic use for the major clinical event endpoints. Conclusions: In a real-world study, treatment with SGLT2 inhibitors in elderly patients with HFrEF and CKD was associated with a lower rate of all-cause mortality.
Becerra et al. (Fri,) conducted a observational in Heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) (n=173). SGLT2 inhibitors was evaluated on all-cause mortality (HR 0.324, 95% CI 0.117-0.894). Treatment with SGLT2 inhibitors in elderly patients with HFrEF and CKD was associated with a lower rate of all-cause mortality (HR 0.324; 95% CI 0.117-0.894).